Servier Pharmaceuticals is pleased to announce the appointment of Justin Cidado as Head of U.S. Research.
Justin has been a part of Servier for the past five years, most recently serving as Senior Director, Head of U.S. Cancer Biology. He has played a critical role in shaping the company’s oncology discovery strategy, advancing early research programs, and building a strong, collaborative scientific culture in Boston.
This appointment reflects both Justin’s impact and the continued evolution of Servier’s U.S. Research organization, which plays a central role in identifying and progressing new cancer targets into the early research portfolio. As Head of U.S. Research, Justin will lead the integration of target identification, drug discovery, and translational efforts – helping ensure scientific excellence and alignment across the oncology pipeline.
Throughout his time at Servier, Justin has demonstrated both scientific leadership and a strong commitment to collaboration. He was instrumental in supporting the integration of the Agios oncology research team into Servier, helping maintain momentum and team engagement during a period of significant change. He also developed a structured approach to evaluating and prioritizing new targets, which evolved into the framework now used across research to guide project valuation and decision-making.
“I am honored and excited to step into the role of Head of U.S. Research,” said Dr. Cidado. “My deepest gratitude goes to the Boston Research team who for the last five years have dedicated themselves to building a dynamic, cohesive, and innovative foundation together. I am greatly encouraged by the promising cancer therapeutic programs being advanced by our U.S. team and look forward to collaborating with our global R&D colleagues to develop transformative medicines that improve patients’ lives.”
Prior to joining Servier, Justin held roles of increasing responsibility at AstraZeneca, where he led preclinical discovery efforts and advanced oncology programs, as well as earlier positions at Novartis. He holds a Ph.D. from The Johns Hopkins School of Medicine and has dedicated his career to advancing the next generation of scientific discoveries and translating them into meaningful therapies for patients.